Anavex Life Sciences Corp (AVXL)

[scorman1]

the problem is that the data is confusing with"titration" meaning that all patients do NOT react well to specific doseages. There had been NO breakout of which doseages produce what clinical effect . The FDA wants clarity, not confusion. SAVA gave everyone the same dose pills to mild and moderate and reported all the data. BTW, 47% of all 216 patients in phase 2 with a cognitive gain of 4.7 points, which here would consider "super responders" if AVXL had bothered reported it, but conveniently hasn't